Short title: de novo KCNJ5 mutation causing hyperaldosteronism.
INTRODUCTION
Primary aldosteronism (PA) is the most frequent cause of secondary hypertension (1) . In addition to the predominant sporadic forms of PA there are at least three distinct familial variants, named familial hyperaldosteronism (FH) types I, II and III. FH-III is an autosomal dominant disease clinically distinct from the first two familial forms (2) caused by heterozygous mutations in the KCNJ5 gene encoding the G protein-activated inward rectifier K + channel 4 (Kir3.4) (3) . So far, five germline mutations in the KCNJ5 gene have been identified and functionally characterized in patients with FH-III (4, 5) . All these missense mutations are located near or within the conserved glycine-tyrosine-glycine (GYG) motif of the selectivity filter of the channel. Here we report and characterize a germline missense mutation affecting another conserved residue located N-terminal to the GlyTyrGly signature sequence. This substitution, p.Glu145Gln, previously reported as somatic mutation in sporadic APAs (6) , was identified in a patient with severe hyperaldosteronism that presented in infancy. Interestingly, the importance of this p.Glu145Gln substitution for Kir3.4 function had been predicted and confirmed in vitro (7) a decade before the KCNJ5 mutations were linked to FH-III.
MATERIALS AND METHODS
Detailed Materials and Methods are available on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org.
RESULTS

Case report
The index case is a Caucasian girl, born to nonconsanguineous parents. At the age of 8 weeks poor weight gain was noticed. At the age of 8 months, she displayed failure to thrive, polydipsia and polyuria. At the age of 2 years, her height was 80 cm (SDS=-2.1), weight 12 kg (SDS=-2.7), blood pressure 115/65 mmHg (SBP > 99 th height-corrected percentile for age). The urinary output was 3 L/day, urine specific gravity ranged 1000-1003, serum potassium was 2.3 mmol/L, sodium 140 mmol/l. PA was diagnosed on the basis of extremely elevated serum aldosterone (>5000 pmol/L, normal range 111-830 pmol/L) and suppressed PRA (0.2 ng/mL/h, normal range, 0.98-4.18). Aldosterone remained elevated (>5000 pmol/L) after dexamethasone suppression test (4 ug/day for 2 days). Treatment with spironolactone (50 mg/day) and potassium supplements were started.
At the age of 4 years no difference in the aldosterone/PRA ratio before (>2632) and after (>2849) orthostatic exercise was observed. CT and MRI failed to reveal adrenal masses. At the age of 8 years, the patient was admitted to the Warren Magnuson Clinical Center (National Institutes of Health, NIH, Bethesda, Maryland). At admission she was off spironolactone for 2 weeks. Her height was 134.7 cm (75 th percentile), weight 34.4 kg (90 th percentile) and pubertal stage Tanner B2P2. She was hypertensive (135/100 mm Hg, >99 th height-corrected percentile for age) and serum potassium was 2.3 mmol/L. Serum createnine was 0.6 mg/dL (0.7-1.33 mg/dL). Serum aldosterone was 8365 pmol/L, PRA 0.6 ng/mL/h and serum 18OHcorticosterone 27.0 nmol/L (0. 2-2.3) . Intravenous saline loading test confirmed non-suppressibilty of aldosterone production (8815 pmol/L after saline infusion). A 2-day dexamethasone suppression test showed a decrease of serum aldosterone from 16537 to 9086 pmol/L excluding glucocorticoid-remediable aldosteronism. Adrenal vein sampling was performed displaying bilateral aldosterone overproduction.
Subsequently, she has been treated with spironolactone (50-400 mg/day), potassium chloride and calciumchannel blockers. She remained hypertensive and hypokalemic (serum potassium 2.7-3.9 mmol/L). The patient underwent pubertal development started at 11 years and progressed to Tanner stage B4P4 but no menarche occurred. Because of the low effectiveness of the therapy, bilateral adrenalectomy was recommended, but the family denied the consent.
At the age of 19 she was re-evaluated at NIH. She was on four antihypertensive medications and potassium supplements; serum creatinine was 2.19 mg/dL, potassium 3.2 mmol/L and urine protein/creatinine ratio 2.5 mg/mg. Transthoracic echocardiography revealed mildly dilated aortic root and ascending aorta without left ventricular hypertrophy. The patient consented to bilateral adrenalectomy which was performed laparoscopically (Supplemental Figure S1 ).
Identification of a novel KCNJ5 mutation
Sequencing of the KCNJ5 gene from peripheral blood DNA identified a novel germline heterozygous c.433G>C substitution ( Figure 1A ), that causes a glutamic acid to glutamine substitution at position 145 (p.Glu145Gln). The mutation was absent from the parents peripheral blood DNA ( Figure 1A-B ), thereby indicating a de novo mutation in our patient. An amino acid alignment of Kir3.4 showed that Glu145 is highly conserved among orthologs and paralogs (Supplemental Figure S2 ).
Gene expression study in HAC15 cells
To define the effect of KCNJ5 c.433G>C substitution in adrenal cell function the mutant channel p.Glu145Gln was overexpressed in HAC15 cells and gene expression evaluated by real-time PCR. We observed a significant up-regulation of both CYP11B2 (2.4±0.5 fold; P<0.001) and its transcriptional regulator NR4A2 (60.8±13 fold; P<0.001) in Kir3.4 p.Glu145Gln overexpressing cells, compared to cells expressing the wild-type protein ( Figure 1C ).
Na + -dependent depolarization of adrenal cells expressing Kir3.4 p.Glu145Gln
Whole cell currents in NCI-H295R cells expressing wild-type Kir3.4 were very small and did not change after removal of Na + from the extracellular solution ( Fig. 2A) . In contrast, cells expressing Kir3.4 p.Glu145Gln showed larger inward and outward currents ( Fig. 2A ) under control conditions compared to KCNJ5 WT -transfected cells. The inward current was reduced under Na + -free conditions demonstrating the Na + permeability of the mutant channel. Accordingly, mutant channel expressing cells were strongly depolarized under resting conditions, and hyperpolarized under Na + -free conditions (Fig. 2B ).
Pharmacology of Kir3.4 p.Glu145Gln
Kir3.4 is activated by G-protein-coupled receptors and by high intracellular Na + concentrations (8) .
Accordingly, an inward current was activated in cells expressing wild-type Kir3.4 when 30 mM Na + and 0.5 mM GTP were present in the pipette solution, and when extracellular K + was increased to 50 mM.
Under these conditions, the inward current in KCNJ5 WT transfected cells was inhibited by application of 1 µM tertiapin-Q(9) to the bath (Fig. 2C) . The mutant p.Glu145Gln channel was insensitive to tertiapin-Q ( Fig. 2C) . The L-type Ca 2+ -channel blocker verapamil, previously shown to inhibit other Kir3.4 mutants (10) had no significant effect on Kir3.4 p.Glu145Gln (81±10% remaining inward current, p=0.25, n=10).
Kir3.4 p.Glu145Gln increased cytosolic Ca 2+ levels in adrenal cells.
Under control conditions, Ca 2+ concentration was increased in NCI-H295R cells expressing the mutant channel, compared to cells expressing wild-type Kir3.4 (Fig. 2D ). In Na + -free extracellular solution (a condition where the Na + /Ca 2+ exchanger, NCX, is inhibited or even works in reversed mode), Ca 2+ concentration was further increased in cells expressing Kir3.4 p.Glu145Gln. Application of verapamil under control conditions led to a reduction of Ca 2+ concentration in cells expressing the mutant, although Ca 2+ was not normalized to wild-type levels (Fig. 2D ). Stimulation of cells with 15 mM K + increased Ca 2+ in wild-type Kir3.4 expressing cells, but had a minor effect on cells expressing the p.Glu145Gln channel, mainly because the mutant expressing cells were already strongly depolarized under control conditions ( Fig. 2B ). Calcium increase in wild-type Kir3.4 expressing cells was smaller than in untransfected cells, indicating that the wild-type channel was activated under these conditions, therefore reducing depolarization and subsequent activation of voltage-activated Ca 2+ channels. The effect of stimulation with angiotensin II was similar in wild-type and mutant KCNJ5 transfected cells (Fig. 2D) .
DISCUSSION
An important breakthrough in the understanding of the molecular mechanisms underlying autonomous aldosterone production in PA has been made recently by the discovery of germline and somatic mutations in genes that affecting calcium entry in adrenal zona glomerulosa cells (3, 11, 12) . KCNJ5 gene mutations, which cause both FH-III and a consistent proportion of sporadic APAs (3, 4) , impair the selectivity filter of the Kir3.4 K + channel, leading to angiotensin II -independent depolarization of adrenal cells and constitutive aldosterone production.
Ion selectivity of all K + channels (including Kir3.4) was shown to be dependent on the presence of specific amino acids within the P-loop domain (13) . In addition to the GlyTyrGly motif, that coordinates dehydrated K + ions as they move through the channel (14), further structural features of the channels are necessary to confer K + selectivity (15) . Yang et al. demonstrated that two oppositely charged conserved residues in Kir2.1, Glu138 and Arg148, could form a salt bridge (16) (6).
Herein we describe the first case of FH-III associated with this molecular defect and characterize the functional consequences of the mutation in adrenal cells. Electrophysiological studies using adrenocortical NCI-H295R cells revealed that loss of ion selectivity of the p.Glu145Gln mutated channel led to cell membrane depolarization as observed in Xenopus oocytes (7) . Ca 2+ measurements in adrenocortical cells disclosed pathologically increased cytosolic Ca 2+ levels, which were further increased upon removal of extracellular Na + . The latter Ca 2+ increase was likely caused by the reversed mode of NCX that was promoted by Na + loading of the cells. Besides the activation of voltage-gated Ca 2+ channels and the Ca 2+ influx through the mutated Kir3.4 channel itself (17), impaired NXC-mediated Ca 2+ extrusion or even reversed transport mode could account for the severe phenotype of cells expressing mutant Kir3.4. Taken together, the effects of the p.Glu145Gln mutant expressed in adrenal cells were reminiscent to those reported for other, mostly somatic mutations of Kir3.4 (10, 18) Interestingly, expression of the Kir3.4 wildtype channel diminished the Ca 2+ signal provoked by high K + indicating a physiological function of Kir3.4 in limiting overwhelming aldosterone secretion rather than setting the baseline activity of glomerulosa cells.
In accordance with an increase in Ca 2+ influx, expression of the mutated channel in HAC15 adrenal cells increased NR4A2 and CYP11B2 transcript levels compared to wild type KCNJ5 expressing cells, supporting a mechanistic role for this mutation in the activation of aldosterone production.
Based on the limited number of cases reported to date, the clinical severity of FH-III varies significantly, ranging from early to late manifestations with mild to severe hypertension and different responsiveness to medical therapy (4, 5) . So far it is not clear whether a genotype-phenotype correlation exists in FH-III. The patient described herein is one of the most severe cases reported so far. The girl presented with severe hyperaldosteronism in the first months of life with profound hypokalemia mimicking nephrogenic diabetes insipidus. Interestingly, in spite of the extreme hyperaldosteronism and hypokalemia, blood pressure was only slightly elevated. This is in agreement with other reports of congenital mineralocorticoid excess in children, showing that overt hypertension is not uniformly present in younger patients (19, 20) .
Treatment with large doses of spironolactone and potassium supplementation in our patient was only partially effective. Addition of calcium channel blockers did not result in a significant improvement and had no effect on plasma aldosterone concentration in agreement with the experimental data showing no effect of the L-type calcium-channel blocker verapamil on the mutated channel.
In conclusion, we report the identification of a novel KCNJ5 germline mutation responsible for severe hyperaldosteronism that presented in infancy with symptoms of diabetes insipidus. This p.Glu145Gln substitution, as for other KCNJ5 mutations, causes Na + dependent cell membrane depolarization and disturbed intracellular Ca 2+ homeostasis in adrenocortical cells. Indeed, the findings of this study further elucidate the etiology of FH-III and expand our knowledge of this rare condition. (n=5), wild-type KCNJ5 (WT, n=10), or mutant KCNJ5 encoding the p.Glu145Gln substitution (E145Q, n=16). Currents and voltage were measured under control (ctrl, normal Ringer solution) and Na + -free (using N-methyl-D-glucamine chloride, NMDG + , instead of NaCl) conditions. (C) The tertiapin-Q (1 µM) sensitive current of cells expressing the KCNJ5 wild-type (WT; n=12) or mutant KCNJ5 encoding the p.Glu145Gln substitution (E145Q; n=6) is shown. To stimulate currents in cells expressing the wild-type channel, the pipette solution was supplemented with Na + (30 mM) and GTP (0.5 mM) and bath K + was increased (50 mM K + ). (D) Fura-2 Ca 2+ measurements: Traces show mean values of 340 nm/380 nm ratios ±
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Materials and methods
DNA analysis.
The study was approved by the institutional review board, and the patient and her parents gave informed consent for DNA analysis. Genomic DNA was extracted from peripheral leukocytes by standard procedure.
The coding sequence of KCNJ5 gene was amplified by PCR in two fragments and the amplification products were purified and directly sequenced using automated DNA sequencer (3130 Genetic Analyzer, Applied Biosystems, Foster City, CA, USA). The sequences of primers are available on request. Genbank cDNA entry with accession number NM_000890.3 was used as a reference sequence.
Cell culture and transfection
For gene expression studies HAC15 human adrenocortical carcinoma cells were cultured in Dulbecco's Modified Eagle/F12 medium (Invitrogen, Carlsband, CA) supplemented with 10% Cosmic Calf Serum (HyClone, Logan, UT), 1% insulin/transferrin/selenium Premix (BD Biosciences, Sparks, MD) and antibiotics.
HAC15 cells were electroporated using the Amaxa electroporator (program X005, Amaxa Biosystems, Cologne, Germany) in 100 μL of nucleofector solution R. After electroporation, cells were plated in 6-well plates with 5 mL of growth medium/well and allowed to recover for 24 h, then starved overnight in 0.1% low serum media (0.1% Cosmic calf serum and antibiotics).
For electrophysiological studies adrenocortical carcinoma NCI-H295R cells (CLS, Eppelheim, Germany) were cultured in a commercial cell-line specific DMEM/F12 medium containing: 15 mM HEPES, 6.25 µg/mL insulin, 6.25 µg/mL transferrin, 6.25 ng/mL selenium, 1.25 mg/mL bovine serum albumin, 5.35 mg/mL linoleic acid, and 2.5% Nu-Serum I (MG-42, CLS, Eppelheim, Germany). The cells were maintained at 37°C under a humid atmosphere of 95% air/5% CO2. Plasmids (pMA-RQ (ampR)) containing the cDNA sequence of wildtype human KCNJ5 and KCNJ3 were purchased from Invitrogen/Geneart. For expression in mammalian cells, cDNAs were subcloned into the bicistronic expression vector pIRES-CD8 (1) . The plasmid containing the cDNA sequence of mutated KCNJ5 E145Q was generated by site-directed
